BNTC — Benitec Biopharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1808898 ·
Last close
$11.18
Market Cap
$384.08M
52W High
$14.33
52W Low
$9.95
ADV30
87,653
Next earnings
2026-05-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -13,582,000 | -11,935,000 | 187,000,000 | 184,761,000 | 3,668,000 |
| Dec 2025 | 0 | — | -13,377,000 | -11,837,000 | 190,681,000 | 188,790,000 | 3,320,000 |
| Sep 2025 | 0 | — | -9,803,000 | -8,965,000 | 96,027,000 | 94,479,000 | 2,428,000 |
| Jun 2025 | 0 | — | -17,176,000 | -16,147,000 | 99,592,000 | 97,744,000 | 2,297,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,792,000
Investing CF
$-21,000
Financing CF
$101,280,000
CapEx
$-21,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.10
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-260,913,000
Inventory
—
Receivables
$3,000
ST Investments
—
EBIT TTM
$-53,938,000
Pretax Income TTM
$-48,884,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -41,765,000 | -37,917,000 | 99,592,000 | 2,297,000 | — | -23,588,000 |
| Jun 2024 | 0 | -22,490,000 | -21,751,000 | 52,210,000 | 4,962,000 | — | -19,403,000 |
| Jun 2023 | 75,000 | -19,081,000 | -19,562,000 | 4,464,000 | 4,262,000 | — | -18,012,000 |
| Jun 2022 | 73,000 | -17,854,000 | -18,208,000 | 5,973,000 | 3,091,000 | — | -15,899,000 |
| Jun 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-9.42
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $11.33 · call volume: 5 · put volume: 4Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RZLT | Rezolute, Inc. | $385.17M | $4.00 | — |
| CTNM | Contineum Therapeutics, Inc. | $388.76M | $11.88 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $394.57M | $6.04 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $373.09M | $7.33 | — |
| SGMT | Sagimet Biosciences Inc. | $396.47M | $6.48 | — |
News headlines (Yahoo Finance, 1h cache)
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
2026-05-14 12:00 · Yahoo
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of
2026-04-28 11:00 · Yahoo
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, th
2026-03-10 11:00 · Yahoo
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinic
2026-03-09 11:00 · Yahoo
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
2026-02-23 12:00 · Yahoo
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation
2026-02-14 13:27 · Yahoo
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
2026-02-12 13:30 · Yahoo
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
2026-01-11 13:00 · Yahoo
Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?
2025-12-24 14:55 · Yahoo
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
2025-12-05 14:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.